Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206)

NCT06695845 is registered in ClinicalTrials.gov with Jazz Pharmaceuticals as lead sponsor.

NCT NCT06695845
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06695845 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206)
Lead sponsor
Jazz Pharmaceuticals
Phase
Phase 2
Overall status
Recruiting
Start date
January 14, 2025
Completion date
December 31, 2027
Enrollment
200 (estimated)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, colorectal cancer, endometrial cancer, esophageal cancer, gastric cancer, gastroesophageal cancer, her-2 protein overexpression, non-small cell lung cancer, ovarian cancer, pancreatic cancer, salivary gland cancer, urothelial carcinoma